Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction

Cell Cycle

Volumn 6, Issue 5, 2007, Pages 620-625

  Rodríguez, Isabel ^a   Coto, Eliecer ^a,b   Reguero, Julián R ^a,c   González, Pelayo ^a   Andrés, Vicente ^d   Lozano, Iñigo ^a   Martín, María ^a   Alvarez, Victoria ^a   Morís, César ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Instituto de Investigación Nefrológica Fundación Renal   (Spain)

^c Fundación Asturcor   (Spain)

^d INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

Atherosclerosis; Cell cycle genes; Genetic susceptibility vascular smooth muscle cells; Myocardial infarction; Polymorphisms

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN P16; PROTEIN P21; PROTEIN P57; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN MOTIF; SMOKING;

MUS;

EID: 33947325935     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.5.3927     Document Type: Article

References (34)

1. Dzau V, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002; 8:1249-56.
2. 1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-63.
3. Andrés V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res 2004; 63:11-21.1.
4. Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. Interleukin-1β inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscl Thromb Vasc Biol 2002; 22:1293-98.
5. Sedding DG, Seay U, Fink L, Heil M, Kummer W, Tillmanns H, Braun-Dullaeus RC. Mechanosensitive p27kip1 regulation and cell cycle entry in vascular smooth muscle cells. Circulation 2003; 108:616-22.
6. Akimoto S, Mitsumata M, Sasaguri T, Yoshida Y. Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1). Circ Res 2000; 86:185-90.
7. Chen D, Walsh K, Wang J. Regulation of cdk2 activity in endothelial cells that are inhibited from growth by cell contact. Arterioscler Thromb Vasc Biol 2000; 20:629-35.
8. Hirano M, Hirano K, Nishimura J, Kanaide H. Transcriptional up-regulation of p27(Kip1) during contact-induced growth arrest in vascular endothelial cells. Exp Cell Res 2001; 271:356-67.
9. Sato J, Nair K, Hiddinga J, Eberhardt NL, Fitzpatrick LA, Katusic ZS, O'Brien T. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res 2000; 47:697-706.
10. Servant MJ, Coulombe P, Turgeon B, Meloche S. Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol 2000; 148:543-56.
11. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998; 82:396-403.
12. cip1 in human atherectomy specimens: Primary stenosis versus restenosis. J Lab Clin Med 2003; 141:179-189.
13. Ihling C, Technau K, Gross V, Schulte-Monting J, Zeiher AM, Schaefer HE. Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor p27/Kip1 and cyclin E in human atherosclerotic tissue: Implications for lesion cellularity. Atherosclerosis 1999; 144:7-14.
14. kip1 protects against diet-induced atherosclerosis. FASEB J 2001; 15:1989-95.
15. kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood 2004; 103:158-61.
16. Takagi Y. Adenovirus-mediated overexpression of a cyclin-dependent kinase inhibitor, p57Kip2, suppressed vascular smooth muscle cell proliferation. Hokkaido Igaku Zasshi 2002; 77:221-30.
17. Nakano N, Urasawa K, Takagi Y, Saito T, Kaneta S, Ishikawa S, Higashi H, Tsutsui H, Hatakeyama M, Kitabatake A. Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells. Biochem Biophys Res Commun 2005; 338:1661-67.
18. Merched AJ, Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation 2004; 110:3830-41.
19. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000; 101:2022-25.
20. Topol EJ, Smith J, Plow EF, Wang QK. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 2006; 15:R117-123.
21. Gonzalez P, DiezJuan A, Coto E, Alvarez V, Reguero JR, Batalla A, Andres V. A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biol 2004; 2:5.
22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
23. González P, Álvarez R, Batalla A, Reguero JR, Álvarez V, Astudillo A, Cubero GI, Cortina A, Coto E. Genetic variation at the chemokines receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191-95.
24. Gonzalez P, GarciaCastro M, Reguero JR, Batalla A, Ordonez AG, Palop RL, Lozano I, Montes M, Alvarez V, Coto E. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet 2006; 43:167-69.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nuc Acids Res 1988; 16:1215.
26. Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 1996; 93:3026-30.
27. Cai Q, Gao YT, Wen W, Shu XO, Jin F, Smith JR, Zheng W. Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene. Cancer Res 2003; 63:5727-30.
28. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, Watanabe A, Hattori E, Shimizu H, Kumakura T, Ebihara M, Meerabux JM, Toru M, Yoshikawa T. A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 2003; 13:271-78.
29. Okamoto I, Krogler J, Endler G, Kaufmann S, Mustafa S, Exner M, Mannhalter C, Wagner O, Pehamberger H. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int J Cancer 2006; 119:1312-15.
30. Fiotti N, Altamura N, Fisicaro M, Carraro N, Adovasio R, Sarra VM, Uxa L, Guarnieri G, Baxter BT, Giansante C. MMP-9 microsatellite polymorphism: Association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis 2005; 182:287-92.
31. Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004; 25:39-47.
32. Naylor LH, Clark EM. d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription. Nucleic Acids Res 1990; 18:1595-1601.
33. Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y. Characterization of the human p57KIP2 gene: Alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 1996; 97:625-31.
34. Li Y, Millikan RC, Newman B, Conway K, Tse CK, Liu ET. P57 (KIP2) polymorphisms and breast cancer risk. Hum Genet 1999; 104:83-88.